Summary of Study ST003286

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002038. The data can be accessed directly via it's Project DOI: 10.21228/M85V5Z This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST003286
Study Title	Interaction between NSCLC cells, CD8+ T cells and immune checkpoint inhibitors potentiates coagulation and promotes metabolic remodeling- new cues on CAT-VTE
Study Summary	Cancer-related thrombosis (CAT) and venous thromboembolism (VTE) are common cancer-related sequelae linked with high mortality, therefore finding predictive indicators is critical. Immune checkpoint inhibitors (ICI) are utilized in cancer immunotherapy to activate T lymphocytes against cancer cells. Recent retrospective investigations found that some individuals experienced increased VTE after receiving ICI. We postulated that ICI (anti-CTLA4 and anti-PD1) effect on immunological and cancer cells, as well as their interaction, contributes for an elevated risk of CAT-VTE. Our objective is to investigate this molecular interaction in order to uncover potential prothrombotic indicators. We pharmacologically modulated non-small cell lung cancer (NSCLC) cell lines in co-culture with CD8+ T lymphocytes (T CD8+) obtained from healthy blood donors. Nuclear Magnetic Resonance (NMR) metabolic remodeling analysis revealed differences in extracellular metabolite concentrations after T CD8+ and ICI treatment.
Institute	ITQB NOVA
Last Name	Gonçalves
First Name	Luís
Address	Avenida Republica
Email	lgafeira@itqb.unl.pt
Phone	214469464
Submit Date	2023-11-20
Raw Data Available	Yes
Raw Data File Type(s)	fid
Analysis Type Detail	NMR
Release Date	2024-07-03
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR003415
Treatment Summary:	For the experimental conditions, cells were exposed to Nivolumab (10 mg/mL, OPDIVO), anti-PD1) or Ipilimumab (5 mg/mL, YERVOY, anti-CTLA-4) for 48 h. The Nivolumab and Ipilimumab concentrations were chosen in accordance to the posology indications from the European Medicines Agency (EMA) and using as reference a male adult with 80 kg and 5 L of blood. The conditions were tested in monoculture or in co-culture with TCD8+.

Treatment ID:

TR003415

Treatment Summary:

For the experimental conditions, cells were exposed to Nivolumab (10 mg/mL, OPDIVO), anti-PD1) or Ipilimumab (5 mg/mL, YERVOY, anti-CTLA-4) for 48 h. The Nivolumab and Ipilimumab concentrations were chosen in accordance to the posology indications from the European Medicines Agency (EMA) and using as reference a male adult with 80 kg and 5 L of blood. The conditions were tested in monoculture or in co-culture with TCD8+.